Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MXCT vs TCMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TCMD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

TCMD Overall Winner 6-Pillar Tally: MXCT 1 – 5 TCMD Matrix Metrics: MXCT 3 – 7 TCMD

As of Nov 20, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas TCMD carries 40.1/100 (SELL) at $25.60 (17.4x Forward P/E, 9.4% operating margin).

  • Composite vs. Pillar Nuance: While MXCT currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. TCMD 40.1/100 SELL), TCMD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -85.5% operating margin) and revenue trajectory (+7.1% vs. +48.7% YoY).
  • Defensive Composite Rating Caution: Although TCMD compares more favorably head-to-head, both MXCT (41.7/100 SELL) and TCMD (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MXCT vs TCMD
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25
TCMD NASDAQ Head-to-Head Winner
Tactile Systems Technology, Inc.
Surgical & Medical Instruments & Apparatus
$25.60
-1.5% 1D
Market Cap $582.2M
TTM Revenue $356M
Forward P/E 17.4x
Beta / 30D Vol 0.95β · 52% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 37.0 Fund 44.0 Flow 65.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.4% over 20 days), RSI 54
RSI-14: 53.6 · SMA20: $25.49 · SMA50: $23.76

6-Pillar Scorecard Institutional Category Breakdown (MXCT 1 – 5 TCMD)

Columns: Metric · MXCT · TCMD
1. Valuation Multiples TCMD
Forward P/E N/M 17.4x
Trailing P/E N/M 25.2x
PEG Ratio N/M 17.79x
EV / Revenue 3.9x 1.5x
2. Growth & Scale MXCT
Revenue Growth (YoY) +48.7% +7.1%
Earnings Growth (YoY) +0.0% -13.9%
TTM Revenue (USD) $34M $356M
Market Cap $132.2M $582.2M
3. Profitability & Quality TCMD
Gross Margin 81.0% 77.0%
Operating Margin -85.5% 9.4%
Net Profit Margin -81.4% 6.7%
Return on Equity (ROE) -16.9% 11.0%
4. Balance Sheet & Cash Flow TCMD
Cash Generation (TTM) -$24M $29M
Cash Flow Margin -69.2% 8.1%
Net Cash / Leverage $2.2M Net Debt (0.11x D/E) $58M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TCMD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 54.9% (15th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat TCMD
OpEx & R&D Intensity N/A 67.6% of Rev ($241M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MXCT (3) vs TCMD (7)
Institutional Metric MXCT TCMD Criterion Row Edge
Market Capitalization
Scale
$132.2M $582.2M Larger Scale TCMD
Trailing P/E Ratio
Valuation
N/M 25.2x Lower Multiple TCMD
Forward P/E Ratio
Valuation
N/M 17.4x Lower Multiple TCMD
Revenue Growth (YoY)
Growth
+48.7% +7.1% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-85.5% 9.4% Higher Margin TCMD
Net Profit Margin
Profitability
-81.4% 6.7% Higher Margin TCMD
Return on Equity (ROE)
Capital Efficiency
-16.9% 11.0% Higher ROE TCMD
52-Week Range Position
Momentum
63% ($1–$2) 29% ($21–$38) Stronger Trend MXCT
Beta / 30D Volatility
Risk Regime
1.19β · 96% Vol 0.95β · 52% Vol Lower Realized Risk TCMD
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 40.1 / 100 (SELL) Higher Composite MXCT
Trailing 12M Revenue (USD)
Operating Scale
$34M $356M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.0% 77.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev 17.79x PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($2.2M Net Debt (0.11x D/E)) $29M ($58M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TCMD +12.95 pp
MXCT: -4.2% · TCMD: +8.75%
3M Horizon TCMD +11.03 pp
MXCT: -1.44% · TCMD: +9.59%
6M Horizon MXCT +28.92 pp
MXCT: +31.73% · TCMD: +2.81%
1Y Horizon TCMD +25.06 pp
MXCT: -19.41% · TCMD: +5.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MXCT Revenue TCMD Revenue MXCT Op. Margin TCMD Op. Margin Margin Leader
FY2018 N/A $140M N/A 2.1% TCMD
FY2019 $10M $190M -93.7% 5.5% TCMD
FY2020 $20M $190M -71.6% -1.9% TCMD
FY2021 $20M $210M -84.3% -0.8% TCMD
FY2022 $30M $250M -95.2% -5.2% TCMD
FY2023 $20M $270M -247.7% 6.6% TCMD
FY2024 $20M $290M -230.5% 7.6% TCMD
FY2025 $20M $330M -247.6% 8.9% TCMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TCMD CONSOLIDATION
98d in phase · OBV DISTRIBUTION
Current IV 54.9%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TCMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TCMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $582.2M market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment 67.6% of Rev ($241M)
90D Engineering Disclosures 0 Published

Investor FAQ MXCT vs TCMD Key Questions & Quantitative Answers

As of Nov 20, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas TCMD carries 40.1/100 (SELL) at $25.60 (17.4x Forward P/E, 9.4% operating margin). Composite vs. Pillar Nuance: While MXCT currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. TCMD 40.1/100 SELL), TCMD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -85.5% operating margin) and revenue trajectory (+7.1% vs. +48.7% YoY). Defensive Composite Rating Caution: Although TCMD compares more favorably head-to-head, both MXCT (41.7/100 SELL) and TCMD (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

MXCT leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with TCMD at +7.1% YoY revenue growth and -13.9% YoY earnings growth on $356M TTM revenue (77.0% gross margin, 9.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MXCT cumulative revenue shifted +100.0% while TCMD shifted +135.7%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 67.6% of Rev ($241M) (0 disclosures) for TCMD.

TCMD screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas TCMD trades at 17.4x Forward P/E, 25.2x Trailing P/E, 17.79x PEG, and 1.5x EV/Revenue (8.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus TCMD (11.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, TCMD carries 54.9% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.95β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.